HelpAcademyLoginJoin us as a Member

Lakewood-Amedex Biotherapeutics Inc.

Sign in to save Lakewood-Amedex Biotherapeutics Inc. to a watchlist Sign in to set an alert for Lakewood-Amedex Biotherapeutics Inc.
Tickers
LABT
Headquarters
Not recorded
SEC CIK
0002079272
Website
Not recorded

Closing prices

Latest close, 0.24

Prices start 23 Apr 2026.

Closing prices for LABT132 stored closes for LABT from 23 Apr 2026 to 29 Oct 2026. Lowest 0.24 on 29 Oct 2026, highest 86.50 on 23 Apr 2026, latest 0.24 on 29 Oct 2026.Close0.0025.0050.0075.00100.0023 Apr27 Jul29 Oct
132 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
RevenueNot reported in XBRL filings since 2015
Net income (loss)−3,772,008 USD 1 Apr 2026 to 30 Jun 2026 S-1 for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense182,147 USD 1 Jan 2026 to 31 Mar 2026 FY2026 Q110-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses886,750 USD 1 Jan 2026 to 31 Mar 2026 FY2026 Q110-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents11,709 USD At 31 Mar 2026 FY2026 Q110-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities2,000,000 USD At 30 Jun 2026 S-1 for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities3,037,991 USD At 31 Mar 2026 FY2026 Q110-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity4,331,083 USD At 30 Jun 2026 S-1 for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)2,369,688 shares At 3 Aug 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Net income (loss), newest period first
PeriodReported valueFiling
1 Apr 2026 to 30 Jun 2026 −3,772,008 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 −923,291 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 −3,847,637 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 −655,943 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 −539,617 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 −4,855,405 USDS-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filed

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from Lakewood-Amedex Biotherapeutics Inc., newest first
FormFiledWhat it coversDocument
8-KEvent 22 Sep 2026 Current report (8-K)
  • Shareholder vote results (Item 5.07)
View Current report (8-K) filed 29 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-104177 (opens in a new tab)
S-1 Form S-1 View Form S-1 filed 18 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-101512 (opens in a new tab)
424B3 Form 424B3 View Form 424B3 filed 17 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-090808 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 14 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-089380 (opens in a new tab)
DEF 14AEvent 22 Sep 2026 Proxy statement (DEF 14A) View Proxy statement (DEF 14A) filed 10 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-087336 (opens in a new tab)
8-K Current report (8-K)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 15 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-078328 (opens in a new tab)
424B3 Form 424B3 View Form 424B3 filed 22 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-070622 (opens in a new tab)
424B3 Form 424B3 View Form 424B3 filed 22 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-070620 (opens in a new tab)
8-KEvent 15 Jun 2026 Current report (8-K)
  • Material modification to rights of security holders (Item 3.03)
  • Amendments to articles or bylaws; change in fiscal year (Item 5.03)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 17 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-069512 (opens in a new tab)
424B3 Form 424B3 View Form 424B3 filed 26 May 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-061019 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

Insider transactions

All rows for Lakewood-Amedex Biotherapeutics Inc. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction: none stored

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.